ABVC Completes Initial Subject Recruitment in ADHD Drug Study
ABVC BioPharma (Nasdaq: ABVC) has completed the required subject recruitment for an interim analysis on its Phase IIb clinical study evaluating its PDC-1421 capsule as a treatment for ADHD. Data from 69 patients is required for the study’s interim analysis.
ABVC’s eight-week long ADHD Phase IIb clinical study taking place at the University of California San Francisco (UCSF) Medical Center and five Taiwanese medical centers. Sixty-nine subjects enrolled in the study, 50 have completed the study, and 11 are currently undergoing treatment.
ABVC BioPharma Chief Executive Officer Uttam Patil, Ph. D., said, “We received a favorable response from the subjects participating in our ADHD Phase IIb study at all of our sites. Our clinical trials continue to demonstrate that medicine derived from plants can have significant therapeutic benefits, often with few – if any – side effects. We expect to report similar results in our interim analysis report.”
ABVC’s study is a randomized, double-blind, placebo-controlled study involving a total of approximately 100 patients in the United States and Taiwan.
The company’s Phase IIa study successfully achieved its primary endpoints and was accepted by the FDA in October 2020.
The global ADHD treatment market was valued at $16.13 billion in 2022 and is expected to reach $32.14 billion by 2030.
About ABVC BioPharma
ABVC BioPharma is a clinical-stage biopharmaceutical company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus®) under development. For its drug products, the Company utilizes in-licensed technology from its network of world-renowned research institutions to conduct proof-of-concept trials through Phase II of clinical development. ABVC BioPharma’s network of research institutions includes Stanford University, the University of California at San Francisco, and Cedars-Sinai Medical Center. For Vitargus®, the Company intends to conduct global clinical trials through Phase III.